PJ34 hydrochloride
Based on 37 publication(s) in Google Scholar
PJ34 hydrochloride is an inhibitor of PARP1/2 with IC50 of 110 nM and 86 nM, respectively.
For research use only. We do not sell to patients.
- Purity: 99.81%
- CAS No.: 344458-15-7
- Formula: C17H18ClN3O2
- Molecular Weight:331.80
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) PJ34 hydrochloride
More- Nat Aging. 2024 Jun;4(6):771-782. [Abstract]
- Autophagy. 2025 Oct;21(10):2168-2191. [Abstract]
- Sci Adv. 2026 Jan 2;12(1):eady1681. [Abstract]
- Cell Death Dis. 2026 Mar 23;17(1):350. [Abstract]
- Cancer Lett. 2021 Nov 1:520:26-37. [Abstract]
- Phytomedicine. 2026 Jun:155:158100. [Abstract]
- Part Fibre Toxicol. 2020 Jun 8;17(1):23. [Abstract]
- Acta Biomater. 2022 Jul 15:147:327-341. [Abstract]
- J Transl Med. 2024 Dec 27;22(1):1153. [Abstract]
- Proc Natl Acad Sci U S A. 2023 Mar 28;120(13):e2213857120. [Abstract]
- Apoptosis. 2021 Dec;26(11-12):600-611. [Abstract]
- Antioxidants (Basel). 2024 Apr 26;13(5):525. [Abstract]
- Free Radic Biol Med. 2022 Feb 1:179:1-10. [Abstract]
- J Invest Dermatol. 2024 Dec;144(12):2695-2705.e8. [Abstract]
- Sci Signal. 2023 Jan 17;16(768):eabh1083. [Abstract]
- Cell Mol Life Sci. 2025 Oct 25;82(1):363. [Abstract]
- Drug Des Devel Ther. 2026 Mar 23:20:561571. [Abstract]
- J Enzyme Inhib Med Chem. 2025 Dec;40(1):2501743. [Abstract]
- Bioorg Chem. 2024 Jun:147:107412. [Abstract]
- Mol Med Rep. 2024 Jun;29(6):102. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2024 Apr 22;1870(5):167190. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Sci Rep. 2017 May 23;7(1):2268. [Abstract]
- Exp Neurol. 2026 Oct:404:115862. [Abstract]
- Neurochem Res. 2026 Jun 12;51(3):192. [Abstract]
- Microbiol Spectr. 2026 Jun 24:e0417825. [Abstract]
- J Virol. 2021 Jul 26;95(16):e0076021. [Abstract]
- Regen Ther. 2023 Nov 10:24:592-601. [Abstract]
- Anim Cells Syst. 2022 Aug 3;26(4):192-202. [Abstract]
- Norges teknisk-naturvitenskapelige universitet. 2025.
- bioRxiv. 2025 March 26.
- Norges teknisk-naturvitenskapelige universitet. 2024.
- bioRxiv. 2024 Sep 19:2024.09.19.613696. [Abstract]
- bioRxiv. 2023 Oct 4.
- Nottingham Trent University. 2023 Sep 12.
- Research Square Print. 2022.
- Patent. US20180263995A1.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
RT-PCR
-
IF
-
Histological Imaging/Staining
Biological Activity
|
PARP 110 nM (IC50) |
PARP-2 86 nM (IC50) |
PARP-1 110 nM (IC50) |
PJ34 inhibits the PARP enzyme activity with an IC50 of 110±1.9 nM. To compare the neuroprotective properties of other PARP inhibitors in PC12 cells, PJ34 is evaluated using by LDH assay. PJ34 treatment also significantly and concentration dependently attenuates cell death at a concentration ranging from 10-7 to 10-5 M[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 344458-15-7
-
Appearance Solid
-
Molecular Weight 331.80
-
Formula C17H18ClN3O2
-
Color Light yellow to yellow
-
SMILES
O=C(NC(C=C1C2=C3C=CC=C2)=CC=C1NC3=O)CN(C)C.Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
Publications (37)
-
Journal Impact Factor
-
Most Recent
-
Nat Aging
Converting cell death into senescence by PARP1 inhibition improves recovery from acute oxidative injury. [Abstract]2024 Jun;4(6):771-782. PMID: 38724734
PJ34 hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Jun;4(6):771-782. [Abstract]
IMR-90 human fibroblasts were incubated with the indicated death inhibitor or vehicle for 2 h, followed by H2O2 treatment (1 mM). Cell survival was measured using an MTS assay 24 h after 1 h H2O2 treatment of cells. The results showed that PJ34 (10 µM; pretreated for 2 h before applying H2O2) protected cells from oxidative stress-induced death, while no rescue was observed for other death inhibitors such as QVD (apoptosis), necrosulfonamide (necroptosis), ferrostatin-1 (ferroptosis), VX-765 (pyroptosis), pepstatin A (cathepsin D and E-induced death) and E64d (cathepsin B and L-induced, and calpain-induced death).
PJ34 hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Jun;4(6):771-782. [Abstract]
IMR-90 human fibroblasts were incubated with the indicated death inhibitor or vehicle for 2 h, followed by H2O2 treatment (1 mM). Cells were stained for PAR polymers after 15 min H2O2 exposure; n = 152 from three independent experiments. Quantification was performed on single cells with images taken from multiple microscopic fields of view. The results showed that cells exposed toH2O2 showed a strong nuclear poly-ADP-ribose (PAR) signal that was significantly suppressed by PJ34 (10 µM; pretreated for 2 h before applying H2O2), indicating an on-target effect of the inhibitor. Scale bar, 150 µm.
PJ34 hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Jun;4(6):771-782. [Abstract]
IMR-90 human fibroblasts were incubated with the indicated death inhibitor (PJ34 (10 µM)) or vehicle for 2 h, followed by H2O2 treatment (1 mM). Fourteen days after treatment cells were analyzed using quantitative PCR with reverse transcription (RT–qPCR) for expression of the indicated mRNAs relative to the housekeeping gene (tubulin); n = 6.
PJ34 hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Jun;4(6):771-782. [Abstract]
Immunofluorescence staining with TOM20 and endogenous HK-II of IMR-90 cells pretreated with vehicle or PJ34 exposed to H2O2 (1 mM); control, n = 94, H2O2 and H2O2 + PJ34 (10 µM; pretreated for 2 h before applying H2O2), n = 87 from three independent experiments, Scale bar, 10 µm. The results showed that incubation with PJ34 in cells exposed to H2O2 was sufficient to retain the mitochondrial pool of HK-II.
PJ34 hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Jun;4(6):771-782. [Abstract]
Mice underwent unilateral kidney IRI with the administration of the PARP inhibitor PJ34 (10 mg/kg) or vehicle. Three days after induction of IRI, kidney tissues were collected for histological and molecular analysis. Periodic acid–Schiff staining was used to detect the necrotic area (defined by a red line), n = 5 for vehicle-treated and n = 6 for PJ34-treated mice. Scale bar, 100 µm. The results showed that IRI was characterized by an increased necrotic area, which was considerably reduced by PJ34 treatment.
-
Autophagy
METTL3-dependent m6A modification of SNAP29 induces "autophagy-mitochondrial crisis" in the ischemic microenvironment after soft tissue transplantation. [Abstract]2025 Oct;21(10):2168-2191. PMID: 40340690 -
Sci Adv
PARP1 stabilizes FOXN3 to suppress pulmonary fibrosis through p38-related feedback regulation. [Abstract]2026 Jan 2;12(1):eady1681. PMID: 41481720 -
Cell Death Dis
2026 Mar 23;17(1):350. PMID: 41872158 -
Cancer Lett
NCAPD2 inhibits autophagy by regulating Ca2+/CAMKK2/AMPK/mTORC1 pathway and PARP-1/SIRT1 axis to promote colorectal cancer. [Abstract]2021 Nov 1:520:26-37. PMID: 34229059 -
Phytomedicine
Echinacoside modulates PARP14-GLUD1 axis to mediate energy metabolism reprogramming and mitochondrial function in diminished ovarian reserve. [Abstract]2026 Jun:155:158100. PMID: 41895093 -
Part Fibre Toxicol
Silica nanoparticles induce lung inflammation in mice via ROS/PARP/TRPM2 signaling-mediated lysosome impairment and autophagy dysfunction. [Abstract]2020 Jun 8;17(1):23. PMID: 32513195 -
Acta Biomater
An auto-photoacoustic melanin-based drug delivery nano-platform for self-monitoring of acute kidney injury therapy via a triple-collaborative strategy. [Abstract]2022 Jul 15:147:327-341. PMID: 35643195 -
J Transl Med
YY1 drives PARP1 expression essential for PARylation of NONO in mRNA maturation during neuroblastoma progression. [Abstract]2024 Dec 27;22(1):1153. PMID: 39731187 -
Proc Natl Acad Sci U S A
Muscle PARP1 inhibition extends lifespan through AMPKα PARylation and activation in Drosophila. [Abstract]2023 Mar 28;120(13):e2213857120. PMID: 36947517 -
Apoptosis
Poly(ADP-ribose) polymerase inhibitor PJ34 protects against UVA-induced oxidative damage in corneal endothelium. [Abstract]2021 Dec;26(11-12):600-611. PMID: 34581992 -
Antioxidants (Basel)
Luteolin Alleviates Cadmium-Induced Kidney Injury by Inhibiting Oxidative DNA Damage and Repairing Autophagic Flux Blockade in Chickens. [Abstract]2024 Apr 26;13(5):525. PMID: 38790630 -
Free Radic Biol Med
Hydroxysafflor yellow A and anhydrosafflor yellow B alleviate ferroptosis and parthanatos in PC12 cells injured by OGD/R. [Abstract]2022 Feb 1:179:1-10. PMID: 34923102 -
J Invest Dermatol
TRPV3-Activated PARP1/AIFM1/MIF Axis through Oxidative Stress Contributes to Atopic Dermatitis. [Abstract]2024 Dec;144(12):2695-2705.e8. PMID: 38823435 -
Sci Signal
Tyrosine kinase inhibitors can activate the NLRP3 inflammasome in myeloid cells through lysosomal damage and cell lysis. [Abstract]2023 Jan 17;16(768):eabh1083. PMID: 36649377 -
Cell Mol Life Sci
LncRNA ENST00000532153.1 alleviates podocyte injury by inhibiting PARP1-mediated PARylation of ATF3 in diabetic kidney disease. [Abstract]2025 Oct 25;82(1):363. PMID: 41137902 -
Drug Des Devel Ther
PJ34 Prevents Trauma-Induced Heterotopic Ossification without Adverse Bone Healing: An in vivo and in vitro Investigation. [Abstract]2026 Mar 23:20:561571. PMID: 41908940 -
J Enzyme Inhib Med Chem
Natural product sennoside B disrupts liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein by inhibiting its RNA-binding activity. [Abstract]2025 Dec;40(1):2501743. PMID: 40371698 -
Bioorg Chem
Identification of FTY720 and COH29 as novel topoisomerase I catalytic inhibitors by experimental and computational studies. [Abstract]2024 Jun:147:107412. PMID: 38696845 -
Mol Med Rep
Network pharmacology combined with experimental validation to investigate the effect of Rongjin Niantong Fang on chondrocyte apoptosis in knee osteoarthritis. [Abstract]2024 Jun;29(6):102. PMID: 38639187 -
Biochim Biophys Acta Mol Basis Dis
MTH1 inhibition synergizes with ROS-inducing agents to trigger cervical cancer cells undergoing parthanatos. [Abstract]2024 Apr 22;1870(5):167190. PMID: 38657912 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Sci Rep
NAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion. [Abstract]2017 May 23;7(1):2268. PMID: 28536482
PJ34 hydrochloride purchased from MedChemExpress. Usage Cited in: Sci Rep. 2017 May 23;7(1):2268. [Abstract]
The PARP inhibitor PJ34 prevents TCDD toxicities while increasing NAD+ levels. (a,b) Western blots on homogenates of liver and thymus glands from CE treated with TCDD or vehicle with or without PJ34.
-
Exp Neurol
PARP1 modulates BBB function via regulating NLRC5 in cerebral endothelial cells during ischemic stroke. [Abstract]2026 Oct:404:115862. PMID: 42235665 -
Neurochem Res
β-Lapachone-Induced Oxidative Stress Causes PARP-Dependent NAD+-Depletion that Affects the Energy Metabolism of Cultured Primary Rat Astrocytes. [Abstract]2026 Jun 12;51(3):192. PMID: 42277481 -
Microbiol Spectr
Cell type-dependent induction of type I interferon and PARP1 activation in astrocytes and neurons during chikungunya virus infection. [Abstract]2026 Jun 24:e0417825. PMID: 42370697 -
J Virol
Inhibition of PARP1 Dampens Pseudorabies Virus Infection through DNA Damage-Induced Antiviral Innate Immunity. [Abstract]2021 Jul 26;95(16):e0076021. PMID: 34037418 -
Regen Ther
2023 Nov 10:24:592-601. PMID: 38034859 -
Anim Cells Syst
Restoration of NAD+ homeostasis protects C2C12 myoblasts and mouse levator ani muscle from mechanical stress-induced damage. [Abstract]2022 Aug 3;26(4):192-202. PMID: 36046029 -
-
-
-
bioRxiv
2024 Sep 19:2024.09.19.613696. PMID: 39345583 -
-
-
-
Solvent & Solubility
H2O : 50 mg/mL (150.69 mM; Need ultrasonic)
DMSO : 10 mg/mL (30.14 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1 mg/mL (3.01 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1 mg/mL (3.01 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protocol
To assess the PARP-1 or PARP-2 inhibitory activity of FR247304, 3-AB, and PJ34, PARP activity is evaluated with minor modifications. PARP enzyme assay is carried out in a final volume of 100 μL consisting of 50 mM Tris-HCl (pH 8.0), 25 mM MgCl2, 1 mM dithiothreitol, 10 μg activated salmon sperm DNA, 0.1 μCi of [adenylate-32P]NAD, 0.2 units of recombinant human PARP for PARP-1 assay or 0.1 units of recombinant mouse PARP-2 for PARP-2 assay, and various concentrations of FR261529 or 3-AB. The reaction mixture is incubated at room temperature (23°C) for 15 min, and the reaction is terminated by adding 200 μL of ice-cold 20% trichloroacetic acid (TCA) and incubated at 4°C for 10 min. The precipitate is transferred onto GF/B filter and washed three times with 10% TCA solution and 70% ethanol. After the filter is dried, the radioactivity is determined by liquid scintillation counting.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
PC12 cell cultured are grown in Dulbecco's modified Eagle's medium supplemented with 5% (v/v) fetal calf serum, 5% (v/v) horse serum, and a 1% (v/v) penicillin-streptomycin antibiotics mixture. Cells are grown in an atmosphere of 95% air and 5% CO2 at 37°C. For all experiment, cells are seeded at a density of 4×104 cells/well in 96-well culture plates and allowed to attach overnight. For assessment of cell viability, hydrogen peroxide-induced cytotoxicity is quantified by a standard measurement of LDH release with the use of the LDH assay kit. Briefly, 6 h after hydrogen peroxide exposure, 20 μL of medium of each well is collected, and the solution prepared from LDH assay kit is added. After incubation at room temperature for 30 min, the reaction is stopped by addition of 1 N HCl, and absorbance is measured at 450 nm using a microplate reader.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Rats[1]
For transient focal ischemia, 9- to 10-week-old male Wistar rats (weighing 274-380 g) are used. FR247304, PJ34, or 3-AB, which is suspended with 0.5% methylcellulose, is administered at doses of 10 and 32 mg/kg for FR247304, 3.2 and 10 mg/kg for PJ34, or 32 and 100 mg/kg for 3-AB intraperitonially twice at 10 min before MCA occlusion and 10 min before recirculation. The administration volume is adjusted to 2 mL/kg.
Mice[2]
Male Swiss albino mice (27-32 g) are used. The PARP inhibitor, PJ34 (1.25, 12.5 or 25 mg/kg) is dissolved in isotonic saline (NaCl, 0.9%) and injected intraperitoneally, in a volume of 10 mL/kg, 15 min before ischemia and again 4 h after the onset of ischemia. Control ischemic mice and sham animals are given vehicle (saline). Naive animals are also included in the studies.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Iwashita A, et al. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia. J Ph [Content Brief]
[2]. Haddad M, et al. Anti-inflammatory effects of PJ34, a poly(ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice. Br J Pharmacol. 2006 Sep;149(1):23-30. [Content Brief]
[3]. Diani-Moore S, et al. NAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion. Sci Rep. 2017 May 23;7(1):2268. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 3.0139 mL | 15.0693 mL | 30.1386 mL | 75.3466 mL |
| 5 mM | 0.6028 mL | 3.0139 mL | 6.0277 mL | 15.0693 mL | |
| 10 mM | 0.3014 mL | 1.5069 mL | 3.0139 mL | 7.5347 mL | |
| 15 mM | 0.2009 mL | 1.0046 mL | 2.0092 mL | 5.0231 mL | |
| 20 mM | 0.1507 mL | 0.7535 mL | 1.5069 mL | 3.7673 mL | |
| 25 mM | 0.1206 mL | 0.6028 mL | 1.2055 mL | 3.0139 mL | |
| 30 mM | 0.1005 mL | 0.5023 mL | 1.0046 mL | 2.5116 mL | |
| H2O | 40 mM | 0.0753 mL | 0.3767 mL | 0.7535 mL | 1.8837 mL |
| 50 mM | 0.0603 mL | 0.3014 mL | 0.6028 mL | 1.5069 mL | |
| 60 mM | 0.0502 mL | 0.2512 mL | 0.5023 mL | 1.2558 mL | |
| 80 mM | 0.0377 mL | 0.1884 mL | 0.3767 mL | 0.9418 mL | |
| 100 mM | 0.0301 mL | 0.1507 mL | 0.3014 mL | 0.7535 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
PJ34 hydrochloride Related Classifications
HY-13688 Related Classifications
Powered by Bioz